^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

NF1 overexpression

i
Other names: NFNS, NF1, Neurofibromin 1, Neurofibromatosis-Related Protein NF-1, Truncated Neurofibromin 1
Entrez ID:
Related biomarkers:
22d
Overexpression of SYNGAP1 suppresses the proliferation of rectal adenocarcinoma via Wnt/β-Catenin signaling pathway. (PubMed, Discov Oncol)
Moreover, among Ras GTPase-activating proteins, we focused on SYNGAP1, and experimental validation confirmed that the overexpression of SYNGAP1 in READ significantly suppressed READ cell proliferation and increased apoptosis via regulating the Wnt/β-Catenin signaling pathway. These findings underscored the potential significance of SYNGAP1 in READ and provide new insights for further research and treatment.
Journal
|
NF1 (Neurofibromin 1)
|
NF1 overexpression
29d
Molecular diversity in isocitrate dehydrogenase-wild-type glioblastoma. (PubMed, Brain Commun)
A successful glioblastoma management demands biomarker identification, combination therapies and a nuanced approach considering intratumoural variability. These advancements herald a transformative era in glioblastoma comprehension and treatment.
Review • Journal
|
EGFR (Epidermal growth factor receptor) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
|
EGFR expression • IDH wild-type • NF1 overexpression
1year
The oncogenic role of NF1 in gallbladder cancer through regulation of YAP1 stability by direct interaction with YAP1. (PubMed, J Transl Med)
Our findings discovered a novel oncogenic function of NF1 by directly interacting with YAP1 protein and stabilizing YAP1 to protect it from proteasome degradation in NOZ cells. NF1 may serve as a potential therapeutic target in GBC.
Journal
|
NF1 (Neurofibromin 1) • YAP1 (Yes associated protein 1)
|
YAP1 overexpression • NF1 overexpression
over2years
Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance. (PubMed, Oncol Rep)
Next‑generation sequencing revealed that the frequency of inactivating mutations in NF1 were rare (1.8%) in patients with colorectal cancer and were not associated with the protein expression levels of NF1 except for in a small number of cases (0.5%), where the biallelic inactivation of NF1 was observed. To conclude, the present study showed that modification of NF1 expression can affect sensitivity to cetuximab in colorectal cancer cell lines, though a limitation exists in terms of its potential application as a biomarker for RAS and BRAF wild‑type tumors.
Journal
|
BRAF (B-raf proto-oncogene) • NF1 (Neurofibromin 1)
|
BRAF wild-type • NF1 mutation • NF1 overexpression
|
Erbitux (cetuximab)